Health Care Professional zone

• ROMEMA study:  Phase II study with PDE-4 inhibitor roflumilast in patients with mild cognitive impairment (MCI)MCI)
  www.romema.nl
• ROSTMEMA study: Phase II study with PDE-4 inhibitor roflumilast in patients with cognitive sequela after stroke MCI)
  www.rostmema.nl

REPO-STROKE II, the three-component drug repurposing study, starts inclusion of patients.

In preparation

1. Prickaerts, Heckman, Blokland. Investigational phosphodiesterase inhibitors in phase I and phase II clinical trials for Alzhei-mers disease. Expert Opinion on Investigational Drugs, 26:9, 1033-1048
2. Van Duinen et al. Acute administration of roflumilast enhances immediate recall of verbal word memory In healthy young adults. Neuropharmacology 2018; 9131: 31-38.
3. Blokland A et al. Acute treatment with the PDE4 inhibitor roflumilast improves verbal word memory in healthy old individuals: a double blind placebo controlled study. Neurobiology of Aging 2019; 77: 37-43
4. Gilleen J et al. An experimental medicine study of the phophodieesterase-4 inhibitor, roflumilast, on working memory-related brain activity and episodic memory in schizophrenia patients. Psychopharmacology December 2018.

1. 2021 Guideline for the Prevention of Stroke in Patients with Stroke and Transient Ischemic Attack. Stroke Vol52, Issue 7, July 2021 (e364-e467)
2. Economic burden of stroke across Europe: A population-based cost analysis. Eur Stroke J. 2020 Mar;5(1):17-25

1. Zhao M et al. The Burden of Inflammatory Bowel Disease in Europe in 2020. J Crohn’s and colitis 2021: 15; 1573–1587.
2. Raine T et al. ECCO Guidelines on Therapeutics in Ulcerative Colitis: Medical Treatment. Journal of Crohn’s and Colitis, Volume 16, Issue 1, January 2022, Pages 2–17.
3. Torres et al. ECCO Guidelines on Therapeutics in Crohn’s. Journal of Crohn’s and Colitis, 2020, 4–22 Disease: Medical Treatment.

1. Nogales. C et al. Network pharmacology : curing causal mechanisms instead of treating symptoms. Trends in Pharmacological Sciences feb 2022; vol 43, issue 2 : 136-150